首页> 外文期刊>Polymer bulletin >Synthesis and characterization of star-shaped poly(L-lactide)s with an erythritol core and evaluation of their rifampicin-loaded microspheres for controlled drug delivery
【24h】

Synthesis and characterization of star-shaped poly(L-lactide)s with an erythritol core and evaluation of their rifampicin-loaded microspheres for controlled drug delivery

机译:具有赤藓糖醇核的星形聚(L-丙交酯)的合成,表征及其负载利福平的微球用于药物控制递送的评估

获取原文
获取原文并翻译 | 示例
           

摘要

In this paper, a series of star-shaped poly(L-lactide)s (s-PLLA) were synthesized via ring-opening polymerization of L-lactide (LLA) using erythritol as initiator. The structure and properties of s-PLLA were characterized by H-1 NMR, GPC and DSC. Then taking rifampicin (RIF) as the model drug, RIF-loaded s-PLLA microspheres were prepared using an oil-in-water emulsion solvent evaporation method. SEM and size analysis indicated that s-PLLA with high monomer/initiator molar ratios (s-PLLA98 and s-PLLA99) could form regular microspheres with smooth surface and have narrow size distributions, which hold the drugs well. The XRD spectra of the RIF-loaded microspheres demonstrated that s-PLLA and RIF were both in their amorphous state after the encapsulation process, which might be caused by the impediment effect of each other. The in vitro release profiles of the RIF-loaded microspheres showed that the s-PLLA99 microspheres were able to sustain the release of RIF for a considerable period of time (70-80 % within 180 h) and the release profiles of RIF from s-PLLA microspheres followed the Baker-Lonsdale model equation. Therefore, these biodegradable and biocompatible s-PLLA microspheres may find practical applications as drug delivery carriers.
机译:本文以赤藓糖醇为引发剂,通过L-丙交酯(LLA)的开环聚合反应,合成了一系列星形聚(L-丙交酯)(s-PLLA)。 s-PLLA的结构和性质通过H-1 NMR,GPC和DSC表征。然后以利福平(RIF)为模型药物,采用水包油乳液溶剂蒸发法制备了负载RIF的s-PLLA微球。扫描电镜和尺寸分析表明,具有高单体/引发剂摩尔比的s-PLLA(s-PLLA98和s-PLLA99)可以形成规则的微球,表面光滑,尺寸分布窄,可以很好地固定药物。载有RIF的微球的XRD光谱表明,s-PLLA和RIF在包封过程后均处于非晶态,这可能是由于彼此的阻碍作用引起的。加载RIF的微球的体外释放曲线表明,s-PLLA99微球能够在相当长的一段时间内(180小时内70-80%)维持RIF的释放,并且能够从s-PLLA99微球释放RIF。 PLLA微球遵循Baker-Lonsdale模型方程。因此,这些可生物降解和生物相容的s-PLLA微球可作为药物输送载体找到实际应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号